Diabetes Regenerative Product, GLP1-I.N.T.

[mageerobin]

Preliminary blinded results from it’s Phase IIa trial with E1-I.N.T. showed 3 of the first 4 type I diabetes patients had a 35-75% reduction in daytime insulin usage following a 28 day treatment.

JDRF, the world's leading charitable organization funding type 1 diabetes research, will provide milestone-driven payments of up to U.S. $4 million to the project over two years, facilitating the rapid advancement of the GLP1-I.N.T.(TM) diabetes regenerative product into Phase II clinical trials in type 1 diabetes patients

A LITTLE MORE HOPE FOR YOUR DAY!!!!!!! Rob

***Link to Advertising/Sales site removed.***

[mageerobin]

oops! the article did have advertising around the edges. Sorry. :banghead:

Preliminary blinded results from it’s Phase IIa trial with E1-I.N.T. showed 3 of the first 4 type I diabetes patients had a 35-75% reduction in daytime insulin usage following a 28 day treatment.

JDRF, the world's leading charitable organization funding type 1 diabetes research, will provide milestone-driven payments of up to U.S. $4 million to the project over two years, facilitating the rapid advancement of the GLP1-I.N.T.(TM) diabetes regenerative product into Phase II clinical trials in type 1 diabetes patients.

"Regenerating beta cell function in individuals with type 1 diabetes is a major goal of JDRF," said Richard A. Insel, M.D., Executive Vice President of Research at JDRF. "This new partnership between JDRF and Transition Therapeutics Inc. provides an exciting opportunity to accelerate the proof of concept and commercial development of a beta cell regeneration therapy for type 1 diabetes."

Regenerative medicine is emerging as a major focus for diabetes research and drug development. This approach has the potential to offer therapeutics that can restore the body's ability to produce insulin on its own, thereby reducing both the need for insulin injections and the diabetes-associated complications which include heart disease, kidney disease and blindness.

"We are extremely pleased to obtain support from the JDRF to develop GLP1-I.N.T.(TM), a leading regenerative product which may also expand the use of GLP-1 based therapies to insulin-dependent diabetes patients. Achieving islet cell regeneration may hold promise to reverse the underlying cause of the disease," said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.

Transition's Islet Neogenesis Therapy (I.N.T.) products, GLP1-I.N.T.(TM) and E1-I.N.T.(TM) proprietary combination therapy utilizes the regenerative and blood glucose control properties of GLP-1 analogues together with G1's ability to induce differentiation and regeneration of new insulin-producing cells from
islet precursor stem cells.

Source: Transition Therapeutics, Inc.

http://www.jdrf.org/index.cfm?page_id=105816